1. Eshhar Z (1997) Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 45:131–136
2. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI (1999) Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163:507–513
3. Lamers CHJ, Sleijfer S, Willemsen RA, Debets R, Kruit WHJ, Gratama JW, et al (2004) Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes. J Biol Regul Homeost Agents 18:134–140
4. Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, et al (2000) Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 7:1369–1377
5. Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL (1996) Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 157:836–843